Acrux LimitedASX: ACR

Acrux licenses Lenzetto for Australian market for AUD5.4m

· Issued by Acrux Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Acrux Limited has announced the licensing of its product Lenzetto® for the Australian market, which aims to address a shortage of Menopause Hormone Therapy products in the country. The amended agreement with Gedeon Richter Plc includes milestone payments that could total a significant amount over the next two years following the product's launch. The CEO of Acrux expressed that this agreement will benefit both Australian women and the company's financial position.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Acrux Limited on 6ix

Story so far

Earlier from Acrux

Later from Acrux

All Acrux news releases